List of articles with "AbbVie"

RINVOQ® Approval for Vitiligo

RINVOQ® Approval for Vitiligo

USA AbbVie North Chicago RINVOQ Vitiligo
Biotech's $170B Patent Shift

Biotech's $170B Patent Shift

None Oncolytics Biotech AbbVie Genmab
Epcoritamab Phase 3 Results

Epcoritamab Phase 3 Results

USA Epcoritamab AbbVie North Chicago DLBCL
AbbVie and Trump Agreement

AbbVie and Trump Agreement

USA AbbVie North Chicago TrumpRx ALPHAGAN
AbbVie and RemeGen License Agreement

AbbVie and RemeGen License Agreement

United States AbbVie North Chicago RemeGen RC148
AbbVie Expands Arizona Facility

AbbVie Expands Arizona Facility

United States Manufacturing Tempe Arizona AbbVie
West Transfers SmartDose® Rights

West Transfers SmartDose® Rights

United States Exton AbbVie West Pharmaceutical SmartDose
AbbVie Atogepant Approval

AbbVie Atogepant Approval

Japan Tokyo AbbVie Migraine Atogepant
Upadacitinib for Alopecia

Upadacitinib for Alopecia

Japan Tokyo AbbVie Alopecia Areata Upadacitinib
I Know IBD Wins Bronze

I Know IBD Wins Bronze

Japan AbbVie Minato IBD Awareness I Know IBD
Atogepant Trial Insights

Atogepant Trial Insights

USA AbbVie North Chicago Migraine Atogepant
AbbVie ASH 2025 Highlights

AbbVie ASH 2025 Highlights

United States Chicago Blood Cancer AbbVie ASH 2025
ECLIPSE Study Insights

ECLIPSE Study Insights

USA AbbVie North Chicago Eclipse Atogepant
AbbVie ECLIPSE Migraine Data

AbbVie ECLIPSE Migraine Data

USA AbbVie North Chicago Eclipse Atogepant
Atogepant ECLIPSE Results

Atogepant ECLIPSE Results

United States AbbVie North Chicago Atogepant ECLIPSE Study
Upadacitinib Phase 3 Results

Upadacitinib Phase 3 Results

United States AbbVie North Chicago Upadacitinib Non-Segmental Vitiligo
AbbVie at Conference

AbbVie at Conference

United States healthcare AbbVie North Chicago Piper Sandler
New CLL/SLL Treatment

New CLL/SLL Treatment

Japan Tokyo AbbVie CLL venetoclax
AbbVie EPKINLY Approval

AbbVie EPKINLY Approval

United States AbbVie North Chicago Lymphoma EPKINLY
AbbVie Film on Resilience

AbbVie Film on Resilience

United States Los Angeles AbbVie CLL Second Winds
AbbVie Migraine Award Recipients

AbbVie Migraine Award Recipients

United States AbbVie North Chicago resilience Migraine Career Catalyst Award
2026 Best Places to Work

2026 Best Places to Work

United States BridgeBio Des Moines AbbVie BioSpace
AbbVie Q3 2025 Review

AbbVie Q3 2025 Review

United States AbbVie North Chicago Skyrizi RINVOQ
Pediatric Risankizumab

Pediatric Risankizumab

Japan pediatric psoriasis AbbVie Minato-ku Risankizumab
AbbVie Acquires Bretisilocin

AbbVie Acquires Bretisilocin

USA AbbVie North Chicago Gilgamesh Pharmaceuticals Bretisilocin
RINVOQ® Approval

RINVOQ® Approval

USA AbbVie North Chicago IBD RINVOQ
AbbVie ADC Data ESMO

AbbVie ADC Data ESMO

United States ADC AbbVie North Chicago Solid Tumors
SkinMedica® Launches New Moisturizer

SkinMedica® Launches New Moisturizer

United States Irvine AbbVie SkinMedica HA5
BOTOX® Trial Results

BOTOX® Trial Results

United States AbbVie North Chicago Essential Tremor BOTOX®
AbbVie Awards 2023

AbbVie Awards 2023

AbbVie Neko Pharma Jiksak Bioengineering
AbbVie $70 Million Expansion

AbbVie $70 Million Expansion

United States Worcester AbbVie Biologics Manufacturing Bioresearch Center
Pivekimab Sunirine FDA Submission

Pivekimab Sunirine FDA Submission

United States AbbVie North Chicago BPDCN Pivekimab Sunirine
AbbVie North Chicago Facility

AbbVie North Chicago Facility

United States pharmaceutical AbbVie North Chicago
AbbVie ELAHERE® Pricing

AbbVie ELAHERE® Pricing

United Kingdom AbbVie North Chicago Ovarian Cancer ELAHERE
Tavapadon FDA Application

Tavapadon FDA Application

United States Parkinsons AbbVie North Chicago Tavapadon
Upadacitinib in AA

Upadacitinib in AA

USA AbbVie North Chicago Alopecia Areata Upadacitinib
AbbVie Upadacitinib Update

AbbVie Upadacitinib Update

Japan AbbVie Minato-ku Upadacitinib Polyarticular JIA
AbbVie Dividend News

AbbVie Dividend News

United States pharmaceuticals AbbVie North Chicago Dividend Aristocrats
AbbVie Epcoritamab Update

AbbVie Epcoritamab Update

USA Epcoritamab AbbVie North Chicago DLBCL
Upadacitinib Phase III Results

Upadacitinib Phase III Results

USA AbbVie North Chicago Alopecia Areata Upadacitinib
AbbVie at APLAR

AbbVie at APLAR

Japan Fukuoka AbbVie APLAR rheumatic diseases
Risankizumab for Pediatrics

Risankizumab for Pediatrics

Japan Tokyo pediatric psoriasis AbbVie Risankizumab
Weekly Health Recap

Weekly Health Recap

United States New York AbbVie Peanuts Sonic Healthcare
AbbVie Acquires Gilgamesh

AbbVie Acquires Gilgamesh

USA AbbVie North Chicago Bretisilocin Gilgamesh
New Hydra Cleanser

New Hydra Cleanser

United States Irvine AbbVie SkinMedica HA5 Hydration
AbbVie Expands Manufacturing

AbbVie Expands Manufacturing

United States Active Pharmaceutical Ingredient AbbVie North Chicago
AbbVie Q2 2025 Results

AbbVie Q2 2025 Results

USA AbbVie North Chicago Skyrizi RINVOQ
Promising Alopecia Treatment

Promising Alopecia Treatment

USA AbbVie North Chicago Alopecia Areata RINVOQ
AbbVie FDA Approval

AbbVie FDA Approval

USA AbbVie North Chicago CLL VENCLEXTA
AbbVie Art Project

AbbVie Art Project

Japan Tokyo AbbVie Perspectives Art Project

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.